CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
CervoMed (CRVO) had its price target lowered by Roth Mkm from $19.00 to $11.00. They now have a "buy" rating on the stock.
CervoMed (CRVO) had its price target raised by Chardan Capital from $15.00 to $21.00. They now have a "buy" rating on the stock.
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
CervoMed (CRVO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $31.00 price target on the stock.